Last $0.0007 USD
Change Today 0.00 / 0.00%
Volume 4.8M
MCET On Other Exchanges
Symbol
Exchange
OTC US
As of 2:44 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

multicell technologies inc (MCET) Snapshot

Open
$0.0007
Previous Close
$0.0007
Day High
$0.0007
Day Low
$0.0006
52 Week High
03/20/14 - $0.0027
52 Week Low
12/27/13 - $0.0003
Market Cap
2.7M
Average Volume 10 Days
23.3M
EPS TTM
$-0.0003
Shares Outstanding
3.9B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MULTICELL TECHNOLOGIES INC (MCET)

Related News

No related news articles were found.

multicell technologies inc (MCET) Related Businessweek News

No Related Businessweek News Found

multicell technologies inc (MCET) Details

MultiCell Technologies, Inc., a biopharmaceutical company, engages in the development of novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, and cancer. The company’s product portfolio includes MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; MCT-475, a discovery stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers; and MCT-485, a noncoding double stranded micro RNA with tumor cytolytic properties for the treatment of various cancers. It also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

2 Employees
Last Reported Date: 02/28/14
Founded in 1962

multicell technologies inc (MCET) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

multicell technologies inc (MCET) Key Developments

MultiCell Technologies Inc. Files U.S. and International Patent Applications for the Treatment of Liver Cancer

MultiCell Technologies, Inc. has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use. MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in vitro models of hepatocellular carcinoma. MCT-485 is thought to target cancer by delivering a cytotoxic and oncolytic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer. MCT-485 has demonstrated in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma. MultiCell also plans to study MCT-485 in relevant in vitro and animal models for other major cancers. In contrast to other species of RNAs including siRNAs, MCT-485 appears to induce cancer cell death through a biological process called pyroptosis; a caspase 1-dependent self-destruction cell death that involves pro-inflammatory cytokine production. Typically, pyroptosis is triggered by various pathological stimuli. MCT-485 is thought to suppress or modify the amount of mRNA being expressed by various genes linked to the metabolism, proliferation and viability of cancer cells thereby inducing a state of cellular stress within the cancer cell. MCT-485 appears to exert a preferential biological activity on transformed liver cancer cells while showing no effect on normal, non-transformed liver cells.

MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt

MultiCell Technologies, Inc. filed its 10-K on Feb 28, 2014 for the period ending Nov 30, 2013. In this report its auditor, Eide Bailly, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

MultiCell Technologies, Inc. Files U.S. Provisional Patent Application for its New Class of RNA Therapeutics

MultiCell Technologies, Inc. has filed a U.S. provisional patent application concerning composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death. This patent application describes a novel class of very small noncoding double stranded RNA molecules (VSRNAs) which interfere with the basic homeostatic cellular processes in tumor cells. VSRNAs are of molecular size less than 10 bps, yet are surprisingly capable in their ability to affect the metabolism, viability and proliferative rate of tumor cells consistent with a mechanism of action that bypasses completely, or in part, the canonical known pathways and steps of RNA recognition and RNA interference. In contrast to other species of RNAs, VSRNAs can induce cell death through pyroptosis; a specific biological process that also involves pro-inflammatory cytokine production. Pyroptosis results from the capability of VSRNAs to suppress or modify the amount of mRNA expressing various endogenous genes linked to the metabolism, proliferation and viability of cells, thus inducing a state of cellular stress that results in deployment of mediators of innate immunity. VSRNAs described in this Application exert a preferential biological activity on certain tumor cells while showing no effect on normal, non-transformed cells. Since cancer cells are highly metabolically active, they are more reliant on key housekeeping molecules for survival as opposed to normal cells. Through mobilization of stress pathways and non-canonical RNA sensors, VSRNAs have demonstrated the capability of activating the NF-kB pathway and Ca2+ release, resulting in secretion of pre-formed cytokines stored in cell vesicles, and de novo synthesis of cytokines and chemokines. VSRNAs can be formulated, attached or integrated within delivery vehicles that target or express selectively their payload in desired cell types resulting in both immediate and long-term therapeutic effects against cancer. MultiCell is evaluating MCT-485, a VSRNA, in animal models of hepatocellular carcinoma. Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death worldwide. Over 1 million cases of hepatocellular carcinoma are reported annually. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. MCT-485, possessing both oncolytic and immune activating properties, could be superior to currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect. Additionally, due to its unique mechanism of action, MCT-485 could prove effective in killing other types of cancers. MultiCell plans to initiate similar studies in relevant in vitro and animal models for other major cancers. MultiCell Technologies' MCT-485 is a very small noncoding double stranded RNA (VSRNA), and the first of a family of prospective cancer therapeutics. MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485 and other RNAs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MCET:US $0.00 USD 0.00

MCET Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MCET.
View Industry Companies
 

Industry Analysis

MCET

Industry Average

Valuation MCET Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 67.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MULTICELL TECHNOLOGIES INC, please visit www.multicelltech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.